SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,^[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they’re having a girl or boy at-home as early as six weeks into pregnancy.

According to a 2024 consumer survey, 82% of expectant parents want to know the baby's sex before delivery, and the majority – two to one^[2] – said they would prefer to buy a test in-store vs. ordering online.^[3] Today’s expecting parents want to know fetal sex sooner than ever, for preparedness, naming, nursery and registries, as well as bonding and reduced stress.

“Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it,” said Melissa Gonzales, president of women’s health, Myriad Genetics. “By expanding access of the SneakPeek test through national retail partners, we’re making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood.”

The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand’s new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby’s gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over 99% accuracy in detecting a baby’s gender as early as 6 weeks into pregnancy, clinically proven by peer-reviewed, published scientific studies.

Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor’s offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek’s parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.

How the Test Works

The retail test kit includes the patented SneakPeek Snap^® device, which is placed on the user’s upper arm to nearly painlessly collect a blood sample with the simple press of a button. The sample is then mailed to the SneakPeek laboratory in the included, postage-paid envelope. Test results are delivered as early as the same day the sample is received through a celebratory text message and email.

The SneakPeek test is now available in Walmart, Walgreens and CVS stores. Click here to find a store near you.

About SneakPeek

Through the SneakPeek test, Myriad Genetics is on a mission to make DNA-based prenatal information affordable and accessible for all families. For more information, visit sneakpeektest.com and follow the brand on Instagram and Facebook.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company expects that SneakPeek’s expansion into retailers in the United States will improve the products affordability and accessibility so that the test may be available to many more families who want to learn the sex of their baby at-home as early as six weeks into pregnancy and that a product rebrand, new packaging design, and a website centered on the moment of gender discovery are scheduled for launch in 2025. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact
Matt Scalo
(801) 584-3532
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Glenn Farrell
(385) 318-3718
This email address is being protected from spambots. You need JavaScript enabled to view it. 

^[1] In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of 102 pregnant women using the Snap device at 8-15 weeks gestational age. In a separate published study run in 2021, fetal sex was accurately determined in 100% of 134 pregnant women at 7 weeks gestational age. In a 2022 scientific study, SneakPeek accurately determined fetal sex for 100% of 103 women at 6 weeks gestational age.
^[2] Gateway Genomics Research, August 2022; n=200.
^[3] January 2024 Padilla Newsmaker Online Survey of 1,000 women age 21-45 who are trying to conceive, pregnant or have been pregnant.